{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T13:41:58Z","timestamp":1783086118884,"version":"3.54.6"},"reference-count":204,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017478","name":"Usona Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["202110MFE-472921-HTB-272687"],"award-info":[{"award-number":["202110MFE-472921-HTB-272687"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013057","name":"Heffter Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.neuropharm.2025.110413","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T12:02:09Z","timestamp":1741694529000},"page":"110413","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Exploring serotonergic psychedelics as a treatment for personality disorders"],"prefix":"10.1016","volume":"272","author":[{"given":"Brennan M.","family":"Carrithers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon M.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob D.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin L.","family":"Carhart-Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra R.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Broc A.","family":"Pagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miltiadis","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Zeifman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.neuropharm.2025.110413_bib1","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1177\/00221678211022949","article-title":"Participant reports of mindfulness, posttraumatic growth, and social connectedness in psilocybin-assisted group therapy: an interpretive phenomenological analysis","volume":"64","author":"Agin-Liebes","year":"2021","journal-title":"J. Humanist. Psychol."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110413_bib2","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1177\/02698811221080165","article-title":"Prospective examination of the therapeutic role of psychological flexibility and cognitive reappraisal in the ceremonial use of ayahuasca","volume":"36","author":"Agin-Liebes","year":"2022","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110413_bib3","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1037\/adb0000935","article-title":"Reports of self-compassion and affect regulation in psilocybin-assisted therapy for alcohol use disorder: an interpretive phenomenological analysis","volume":"38","author":"Agin-Liebes","year":"2023","journal-title":"Psychol. Addict. Behav."},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110413_bib4","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1001\/jamaoncol.2023.0351","article-title":"Assessment of psilocybin therapy for patients with cancer and major depressive disorder","volume":"9","author":"Agrawal","year":"2023","journal-title":"JAMA Oncol."},{"issue":"9\u201310","key":"10.1016\/j.neuropharm.2025.110413_bib5","first-page":"6","article-title":"Psychedelic experience and the narrative self: an exploratory qualitative study","volume":"27","author":"Amada","year":"2020","journal-title":"J. Conscious. Stud."},{"key":"10.1016\/j.neuropharm.2025.110413_bib6","doi-asserted-by":"crossref","DOI":"10.1177\/00221678221099680","article-title":"Self-actualization and the integration of psychedelic experience: the mediating role of perceived benefits to narrative self-functioning","author":"Amada","year":"2022","journal-title":"J. Humanist. Psychol."},{"issue":"10 Suppl. l","key":"10.1016\/j.neuropharm.2025.110413_bib7","first-page":"1","article-title":"Practice guideline for the treatment of patients with borderline personality disorder","volume":"158","year":"2001","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2025.110413_bib9","series-title":"Diagnostic and Statistical Manual of Mental Disorders","first-page":"733","article-title":"Personality disorders","year":"2022"},{"key":"10.1016\/j.neuropharm.2025.110413_bib8","series-title":"Diagnostic and Statistical Manual of Mental Disorders","first-page":"881","article-title":"Emerging measures and models: alternative model for personality disorders","year":"2022"},{"key":"10.1016\/j.neuropharm.2025.110413_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100538","article-title":"Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: an open-label safety and feasibility pilot study","volume":"27","author":"Anderson","year":"2020","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.neuropharm.2025.110413_bib11","series-title":"Hallucinogenic Drugs and Their Psychotherapeutic Use","first-page":"101","article-title":"LSD in the treatment of criminal psychopaths","author":"Arendsen-Hein","year":"1963"},{"issue":"9","key":"10.1016\/j.neuropharm.2025.110413_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-016025","article-title":"Does psychedelic drug use reduce risk of suicidality? Evidence from a longitudinal community-based cohort of marginalised women in a Canadian setting","volume":"7","author":"Argento","year":"2017","journal-title":"BMJ Open"},{"issue":"12","key":"10.1016\/j.neuropharm.2025.110413_bib13","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1177\/0269881118798610","article-title":"The moderating effect of psychedelics on the prospective relationship between prescription opioid use and suicide risk among marginalized women","volume":"32","author":"Argento","year":"2018","journal-title":"J. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110413_bib14","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1017\/S1092852923001177","article-title":"Cognition in adults with borderline personality disorder","volume":"28","author":"Aslan","year":"2023","journal-title":"CNS Spectr."},{"issue":"23","key":"10.1016\/j.neuropharm.2025.110413_bib15","first-page":"1200","article-title":"The use of lysergic acid diethylamide (LSD) in psychotherapy","volume":"91","author":"Baker","year":"1964","journal-title":"Can. Med. Assoc. J."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110413_bib16","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1038\/s41598-023-49817-4","article-title":"Psychedelics and sexual functioning: a mixed-methods study","volume":"14","author":"Barba","year":"2024","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.neuropharm.2025.110413_bib17","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1176\/appi.ps.20220525","article-title":"Ethical and practical considerations for the use of psychedelics in psychiatry","volume":"74","author":"Barber","year":"2023","journal-title":"Psychiatr. Serv."},{"issue":"12","key":"10.1016\/j.neuropharm.2025.110413_bib18","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1177\/0269881116678781","article-title":"The Challenging Experience Questionnaire: characterization of challenging experiences with psilocybin mushrooms","volume":"30","author":"Barrett","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2025.110413_bib19","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.paid.2017.06.004","article-title":"Neuroticism is associated with challenging experiences with psilocybin mushrooms","volume":"117","author":"Barrett","year":"2017","journal-title":"Pers. Indiv. Differ."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110413_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-59282-y","article-title":"Emotions and brain function are altered up to one month after a single high dose of psilocybin","volume":"10","author":"Barrett","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2025.110413_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyg.2022.824077","article-title":"Psychedelic integration: an analysis of the concept and its practice","volume":"13","author":"Bathje","year":"2022","journal-title":"Front. Psychol."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110413_bib22","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1177\/0022167817706884","article-title":"Patient experiences of psilocybin-assisted psychotherapy: an interpretative phenomenological analysis","volume":"57","author":"Belser","year":"2017","journal-title":"J. Humanist. Psychol."},{"issue":"7\u20138","key":"10.1016\/j.neuropharm.2025.110413_bib23","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/dta.1376","article-title":"Therapeutic mechanisms of classic hallucinogens in the treatment of addictions: from indirect evidence to testable hypotheses","volume":"4","author":"Bogenschutz","year":"2012","journal-title":"Drug Test. Anal."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110413_bib24","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/0269881114565144","article-title":"Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study","volume":"29","author":"Bogenschutz","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2025.110413_bib25","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3389\/fphar.2018.00100","article-title":"Clinical interpretations of patient experience in a trial of psilocybin-assisted psychotherapy for alcohol use disorder","volume":"9","author":"Bogenschutz","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"10","key":"10.1016\/j.neuropharm.2025.110413_bib26","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","article-title":"Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial","volume":"79","author":"Bogenschutz","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.neuropharm.2025.110413_bib27","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1146\/annurev-clinpsy-032511-143058","article-title":"From dysfunction to adaptation: an interactionist model of dependency","volume":"8","author":"Bornstein","year":"2012","journal-title":"Annu. Rev. Clin. Psychol."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110413_bib28","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.euroneuro.2015.01.008","article-title":"Long-term use of psychedelic drugs is associated with differences in brain structure and personality in humans","volume":"25","author":"Bouso","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2025.110413_bib29","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.neubiorev.2018.02.004","article-title":"Serotonergic psychedelics and personality: a systematic review of contemporary research","volume":"87","author":"Bouso","year":"2018","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2025.110413_bib30","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-41145-x","article-title":"Case analysis of long-term negative psychological responses to psychedelics","volume":"13","author":"Bremler","year":"2023","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.neuropharm.2025.110413_bib31","first-page":"5","article-title":"Phenomenal qualities of ayahuasca ingestion and its relation to fringe consciousness and personality","volume":"13","author":"Bresnick","year":"2006","journal-title":"J. Conscious. Stud."},{"key":"10.1016\/j.neuropharm.2025.110413_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2023.1232459","article-title":"The ego in psychedelic drug action - ego defenses, ego boundaries, and the therapeutic role of regression","volume":"17","author":"Buchborn","year":"2023","journal-title":"Front. Neurosci."},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110413_bib33","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1080\/10481885.2023.2264338","article-title":"The bad seed: mystical experience and time travel in the treatment of psychopathy","volume":"33","author":"Burton","year":"2023","journal-title":"Psychoanal. Dialogues"},{"key":"10.1016\/j.neuropharm.2025.110413_bib34","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jad.2024.08.091","article-title":"Validation of the Swiss psychedelic Side effects inventory: standardized assessment of adverse effects in studies of psychedelics and MDMA","volume":"365","author":"Calder","year":"2024","journal-title":"J. Affect. Disord."},{"issue":"7","key":"10.1016\/j.neuropharm.2025.110413_bib35","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study","volume":"3","author":"Carhart-Harris","year":"2016","journal-title":"Lancet Psychiatry"},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110413_bib36","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00213-017-4771-x","article-title":"Psilocybin with psychological support for treatment-resistant depression: six-month follow-up","volume":"235","author":"Carhart-Harris","year":"2018","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110413_bib37","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s00213-017-4701-y","article-title":"Psychedelics and connectedness","volume":"235","author":"Carhart-Harris","year":"2018","journal-title":"Psychopharmacology"},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110413_bib38","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1124\/pr.118.017160","article-title":"REBUS and the anarchic brain: toward a unified model of the brain action of psychedelics","volume":"71","author":"Carhart-Harris","year":"2019","journal-title":"Pharmacol. Rev."},{"issue":"15","key":"10.1016\/j.neuropharm.2025.110413_bib39","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of psilocybin versus escitalopram for depression","volume":"384","author":"Carhart-Harris","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110413_bib40","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1001\/archpsyc.1960.03590090042008","article-title":"Lysergic acid diethylamide (LSD-25) as a facilitating agent in psychotherapy","volume":"2","author":"Chandler","year":"1960","journal-title":"AMA Archive General Psych."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110413_bib41","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/10508619.2022.2148061","article-title":"Psychedelic science of spirituality and religion: an attachment-informed agenda proposal","volume":"33","author":"Cherniak","year":"2023","journal-title":"Int. J. Psychol. Relig."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110413_bib42","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1001\/jamapsychiatry.2016.4287","article-title":"Efficacy of psychotherapies for borderline personality disorder: a systematic review and meta-analysis","volume":"74","author":"Cristea","year":"2017","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110413_bib43","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1037\/a0021212","article-title":"An other perspective on personality: meta-analytic integration of observers' accuracy and predictive validity","volume":"136","author":"Connelly","year":"2010","journal-title":"Psychol. Bull."},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110413_bib44","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/j.paid.2007.12.001","article-title":"A new five-factor model of psychopathology: preliminary psychometric characteristics of the five-dimensional personality test (5DPT)","volume":"44","author":"Coolidge","year":"2008","journal-title":"Pers. Indiv. Differ."},{"key":"10.1016\/j.neuropharm.2025.110413_bib45","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1192\/bjp.189.1.12","article-title":"Violence and psychiatric morbidity in the national household population of Britain: public health implications","volume":"189","author":"Coid","year":"2006","journal-title":"Br. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110413_bib46","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1177\/0269881120967878","article-title":"Development of the psychological insight questionnaire among a sample of people who have consumed psilocybin or LSD","volume":"35","author":"Davis","year":"2021","journal-title":"J. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110413_bib47","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial","volume":"78","author":"Davis","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.neuropharm.2025.110413_bib48","series-title":"Antagonism and Crime","first-page":"297","author":"DeLisi","year":"2019"},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110413_bib49","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s11126-023-10027-w","article-title":"Correlates of homelessness among adults with personality disorder","volume":"94","author":"Dell","year":"2023","journal-title":"Psychiatr. Q."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110413_bib50","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/02791072.1998.10399715","article-title":"Dr. Leary's concord prison experiment: a 34-year follow-up study","volume":"30","author":"Doblin","year":"1998","journal-title":"J. Psychoact. Drugs"},{"issue":"11","key":"10.1016\/j.neuropharm.2025.110413_bib51","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1038\/npp.2016.82","article-title":"LSD acutely impairs fear recognition and enhances emotional empathy and sociality","volume":"41","author":"Dolder","year":"2016","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110413_bib52","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00213-018-5085-3","article-title":"Ayahuasca improves emotion dysregulation in a community sample and in individuals with borderline-like traits","volume":"236","author":"Dom\u00ednguez-Clav\u00e9","year":"2019","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110413_bib53","doi-asserted-by":"crossref","DOI":"10.1002\/hup.2807","article-title":"Ayahuasca may help to improve self-compassion and self-criticism capacities","volume":"37","author":"Dom\u00ednguez-Clav\u00e9","year":"2022","journal-title":"Hum. Psychopharmacol. Clin. Exp."},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110413_bib54","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/JCP.0000000000001428","article-title":"Ayahuasca improves self-perception of speech performance in subjects with social anxiety disorder: a pilot, proof-of-concept, randomized, placebo-controlled trial","volume":"41","author":"dos Santos","year":"2021","journal-title":"J. Clin. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110413_bib55","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/BF00408333","article-title":"Clinical prediction of insightful response to a single large dose of LSD","volume":"9","author":"Eggert","year":"1966","journal-title":"Psychopharmacologia"},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110413_bib56","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1097\/00005053-195812000-00006","article-title":"Psychotherapy with lysergic acid diethylamide","volume":"127","author":"Eisner","year":"1958","journal-title":"J. Nerv. Ment. Dis."},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110413_bib57","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/acps.12904","article-title":"Effects of psilocybin therapy on personality structure","volume":"138","author":"Erritzoe","year":"2018","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.neuropharm.2025.110413_bib58","series-title":"StatPearls. Treasure Island (FL)","article-title":"Personality disorder. [Updated 2023 apr 17]","author":"Fariba","year":"2023"},{"key":"10.1016\/j.neuropharm.2025.110413_bib59","series-title":"The Therapeutic Use of Ayahuasca","first-page":"183","article-title":"Assessment of the psychotherapeutic effects of ritual ayahuasca use on drug dependency: a pilot study","author":"Fern\u00e1ndez","year":"2014"},{"key":"10.1016\/j.neuropharm.2025.110413_bib60","series-title":"Psychodynamic Psychiatry in Clinical Practice","author":"Gabbard","year":"2014"},{"key":"10.1016\/j.neuropharm.2025.110413_bib61","series-title":"Long-term Psychodynamic Psychotherapy: A Basic Text","author":"Gabbard","year":"2017"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110413_bib62","first-page":"1","article-title":"Psychotherapy of personality disorders","volume":"9","author":"Gabbard","year":"2000","journal-title":"J. Psychother. Pract. Res."},{"key":"10.1016\/j.neuropharm.2025.110413_bib63","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-28099-8_1163-1","article-title":"Self-directedness","volume":"1\u20133","author":"Garcia","year":"2017","journal-title":"Encycloped. Personali Individual Diff."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110413_bib64","first-page":"3","article-title":"Psycholytic therapy with MDMA and LSD in Switzerland","volume":"5","author":"Gasser","year":"1995","journal-title":"MAPS Newsletter"},{"issue":"7","key":"10.1016\/j.neuropharm.2025.110413_bib65","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/NMD.0000000000000113","article-title":"Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases","volume":"202","author":"Gasser","year":"2014","journal-title":"J. Nerv. Ment. Dis."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110413_bib66","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/0269881114555249","article-title":"LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects","volume":"29","author":"Gasser","year":"2015","journal-title":"J. Psychopharmacol."},{"issue":"18","key":"10.1016\/j.neuropharm.2025.110413_bib67","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression","volume":"387","author":"Goodwin","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2025.110413_bib68","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1038\/s41386-023-01648-7","article-title":"Psilocybin for treatment-resistant depression in patients taking a concomitant SSRI medication","volume":"48","author":"Goodwin","year":"2023","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2025.110413_bib69","article-title":"The effect of psychedelics on individuals with a personality disorder: results from two prospective cohort studies","author":"Gordon","year":"2024","journal-title":"Res. Square"},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110413_bib70","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s00213-006-0457-5","article-title":"Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance","volume":"187","author":"Griffiths","year":"2006","journal-title":"Psychopharmacology"},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110413_bib71","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1177\/0269881108094300","article-title":"Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later","volume":"22","author":"Griffiths","year":"2008","journal-title":"J. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110413_bib72","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s00213-011-2358-5","article-title":"Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects","volume":"218","author":"Griffiths","year":"2011","journal-title":"Psychopharmacology"},{"issue":"12","key":"10.1016\/j.neuropharm.2025.110413_bib73","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110413_bib74","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/0269881117731279","article-title":"Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors","volume":"32","author":"Griffiths","year":"2018","journal-title":"J. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110413_bib76","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1037\/per0000678","article-title":"Perception of stigma across diagnostic models of personality pathology","volume":"15","author":"Hein","year":"2024","journal-title":"Personality Disorders"},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110413_bib77","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/0191-8869(85)90148-5","article-title":"Individual differences in reaction to the abuse of LSD","volume":"6","author":"Hemsley","year":"1985","journal-title":"Pers. Indiv. Differ."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110413_bib78","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1177\/0269881113513851","article-title":"Hallucinogen use predicts reduced recidivism among substance-involved offenders under community corrections supervision","volume":"28","author":"Hendricks","year":"2014","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110413_bib79","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/0269881117735685","article-title":"The relationships of classic psychedelic use with criminal behavior in the United States adult population","volume":"32","author":"Hendricks","year":"2018","journal-title":"J. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110413_bib80","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1053\/comp.2000.7423","article-title":"Personality and substance use disorders as predictors of criminality","volume":"41","author":"Hernandez-Avila","year":"2000","journal-title":"Compr. Psychiatry"},{"key":"10.1016\/j.neuropharm.2025.110413_bib81","doi-asserted-by":"crossref","DOI":"10.1001\/jamapsychiatry.2024.2546","article-title":"Adverse events in studies of classic psychedelics: a systematic review and meta-analysis","author":"Hinkle","year":"2024","journal-title":"JAMA Psychiatry"},{"issue":"9299","key":"10.1016\/j.neuropharm.2025.110413_bib82","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1016\/S0140-6736(01)07216-6","article-title":"Death by homicide, suicide, and other unnatural causes in people with mental illness: a population-based study","volume":"358","author":"Hiroeh","year":"2001","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110413_bib83","first-page":"160","article-title":"The perilous policy of Oregon's psilocybin services","volume":"51","author":"Holoyda","year":"2023","journal-title":"J. Am. Academy Psychiat. Law"},{"key":"10.1016\/j.neuropharm.2025.110413_bib84","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.711255","article-title":"Role of the 5-ht2a receptor in acute effects of LSD on empathy and circulating oxytocin","volume":"12","author":"Holze","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110413_bib85","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.biopsych.2022.08.025","article-title":"Lysergic acid diethylamide\u2013assisted therapy in patients with anxiety with and without a life-threatening illness: a randomized, double-blind, placebo-controlled phase II study","volume":"93","author":"Holze","year":"2023","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2025.110413_bib86","first-page":"1","article-title":"LSD-assisted therapy in patients with anxiety: open-label prospective 12-month follow-up","author":"Holze","year":"2024","journal-title":"Br. J. Psychiatr."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110413_bib87","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1521\/pedi.2011.25.3.305","article-title":"Personality assessment in DSM-5: empirical support for rating severity, style, and traits","volume":"25","author":"Hopwood","year":"2011","journal-title":"J. Pers. Disord."},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110413_bib88","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1080\/00223891.2017.1420660","article-title":"Validity of the DSM-5 levels of personality functioning scale-self report","volume":"100","author":"Hopwood","year":"2018","journal-title":"J. Pers. Assess."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110413_bib89","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1192\/bjp.bp.108.058552","article-title":"DSM-IV personality disorders in the WHO world mental health surveys","volume":"195","author":"Huang","year":"2009","journal-title":"Br. J. Psychiatr."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110413_bib90","doi-asserted-by":"crossref","first-page":"14","DOI":"10.4088\/JCP.08r04526gre","article-title":"Effectiveness of pharmacotherapy for severe personality disorders: meta-analyses of randomized controlled trials","volume":"71","author":"Ingenhoven","year":"2010","journal-title":"J. Clin. Psychiatr."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110413_bib91","article-title":"Could psychedelics treat personality disorders?","volume":"8","author":"Iliff","year":"2022","journal-title":"J. Addiction Sci."},{"issue":"S180","key":"10.1016\/j.neuropharm.2025.110413_bib92","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1600-0447.1964.tb04950.x","article-title":"Three years' experience with the use of LSD as an aid in psychotherapy","volume":"39","author":"Johnsen","year":"1964","journal-title":"Acta Psychiatr. Scand."},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110413_bib93","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/0269881108093587","article-title":"Human hallucinogen research: guidelines for safety","volume":"22","author":"Johnson","year":"2008","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110413_bib94","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3109\/00952990.2016.1170135","article-title":"Long-term follow-up of psilocybin-facilitated smoking cessation","volume":"43","author":"Johnson","year":"2017","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"10.1016\/j.neuropharm.2025.110413_bib95","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.neuropharm.2018.05.012","article-title":"The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act","volume":"142","author":"Johnson","year":"2018","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110413_bib96","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/02791072.2020.1842569","article-title":"The psychedelic personality: personality structure and associations in a sample of psychedelics users","volume":"53","author":"Johnstad","year":"2021","journal-title":"J. Psychoact. Drugs"},{"key":"10.1016\/j.neuropharm.2025.110413_bib97","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyg.2023.1104627","article-title":"Psychedelic unselfing: self-transcendence and change of values in psychedelic experiences","volume":"14","author":"K\u00e4h\u00f6nen","year":"2023","journal-title":"Front. Psychol."},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110413_bib98","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1111\/j.1745-8315.2011.00456.x","article-title":"Limitations to the capacity to love","volume":"92","author":"Kernberg","year":"2011","journal-title":"Int. J. Psychoanal."},{"key":"10.1016\/j.neuropharm.2025.110413_bib99","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.623985","article-title":"Psychedelic communitas: intersubjective experience during psychedelic group sessions predicts enduring changes in psychological wellbeing and social connectedness","volume":"12","author":"Kettner","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110413_bib100","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.721537","article-title":"Persisting effects of ayahuasca on empathy, creative thinking, decentering, personality, and well-being","volume":"12","author":"Kiraga","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110413_bib101","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.883869","article-title":"Decreases in state and trait anxiety post-psilocybin: a naturalistic, observational study among retreat attendees","volume":"13","author":"Kiraga","year":"2022","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.neuropharm.2025.110413_bib102","series-title":"Current Topics in Behavioral Neurosciences","doi-asserted-by":"crossref","DOI":"10.1007\/7854_2024_515","article-title":"Guiding through challenging psychedelic experiences and \"bad trips.\"","author":"Koslowski","year":"2024"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110413_bib103","article-title":"A suicide attempt following psilocybin ingestion in a patient with no prior psychiatric history","volume":"2","author":"Kramer","year":"2023","journal-title":"Psychiatry Res. Case Rep."},{"issue":"9","key":"10.1016\/j.neuropharm.2025.110413_bib104","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1017\/S0033291711002674","article-title":"Initial construction of a maladaptive personality trait model and inventory for DSM-5","volume":"42","author":"Krueger","year":"2012","journal-title":"Psychol. Med."},{"key":"10.1016\/j.neuropharm.2025.110413_bib105","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1146\/annurev-clinpsy-032813-153732","article-title":"The role of the DSM-5 personality trait model in moving toward a quantitative and empirically based approach to classifying personality and psychopathology","volume":"10","author":"Krueger","year":"2014","journal-title":"Annu. Rev. Clin. Psychol."},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110413_bib106","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1080\/02791072.2017.1361559","article-title":"Nourishing the spirit: exploratory research on ayahuasca experiences along the continuum of recovery from eating disorders","volume":"49","author":"Lafrance","year":"2017","journal-title":"J. Psychoact. Drugs"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110413_bib107","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/YCO.0000000000000211","article-title":"Avoidant personality disorder as a social anxiety phenotype: risk factors, associations, and treatment","volume":"29","author":"Lampe","year":"2016","journal-title":"Curr. Opin. Psychiatr."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110413_bib108","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1037\/h0088612","article-title":"A new behavior change program using psilocybin","volume":"2","author":"Leary","year":"1965","journal-title":"Psychother. Theory Res. Pract."},{"issue":"8","key":"10.1016\/j.neuropharm.2025.110413_bib109","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1002\/hbm.22833","article-title":"Finding the self by losing the self: neural correlates of ego-dissolution under psilocybin","volume":"36","author":"Lebedev","year":"2015","journal-title":"Hum. Brain Mapp."},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110413_bib110","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1177\/07067437231225937","article-title":"Informed consent to psychedelic-assisted psychotherapy: ethical considerations","volume":"69","author":"Lee","year":"2024","journal-title":"Canadian J. Psychiatry. Revue canadienne de Psychiatrie"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110413_bib111","doi-asserted-by":"crossref","DOI":"10.1093\/nc\/nix016","article-title":"Self unbound: ego dissolution in psychedelic experience","volume":"2017","author":"Letheby","year":"2017","journal-title":"Neurosci. Consciousness"},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110413_bib112","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0300501","article-title":"The therapeutic alliance between study participants and intervention facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder","volume":"19","author":"Levin","year":"2024","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110413_bib113","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S0191-8869(96)00143-2","article-title":"LSD response in Eysenckian trait types identified by polypredictive CFA","volume":"21","author":"Lienert","year":"1996","journal-title":"Pers. Indiv. Differ."},{"key":"10.1016\/j.neuropharm.2025.110413_bib114","doi-asserted-by":"crossref","DOI":"10.1016\/j.concog.2019.05.008","article-title":"Absorption and spiritual experience: a review of evidence and potential mechanisms","volume":"73","author":"Lifshitz","year":"2019","journal-title":"Conscious. Cognit."},{"key":"10.1016\/j.neuropharm.2025.110413_bib115","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jrp.2019.05.012","article-title":"The basic trait of antagonism: an unfortunately underappreciated construct","volume":"81","author":"Lynam","year":"2019","journal-title":"J. Res. Pers."},{"key":"10.1016\/j.neuropharm.2025.110413_bib116","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2023.1267611","article-title":"Cross-validation of the ego dissolution scale: implications for studying psychedelics","volume":"17","author":"Lynn","year":"2023","journal-title":"Front. Neurosci."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110413_bib117","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s12264-016-0027-8","article-title":"Genetic and neuroimaging features of personality disorders: state of the art","volume":"32","author":"Ma","year":"2016","journal-title":"Neurosci. Bull."},{"issue":"11","key":"10.1016\/j.neuropharm.2025.110413_bib118","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1177\/0269881111420188","article-title":"Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness","volume":"25","author":"MacLean","year":"2011","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2025.110413_bib119","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3389\/fphar.2018.00256","article-title":"Individual experiences in four cancer patients following psilocybin-assisted psychotherapy","volume":"9","author":"Malone","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110413_bib120","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.647909","article-title":"Sustained, multifaceted improvements in mental well-being following psychedelic experiences in a prospective opportunity sample","volume":"12","author":"Mans","year":"2021","journal-title":"Front. Psychiatr."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110413_bib121","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/02698811241232548","article-title":"Psychiatric risks for worsened mental health after psychedelic use","volume":"38","author":"Marrocu","year":"2024","journal-title":"J. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110413_bib122","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/02791072.2019.1580804","article-title":"Sub-acute effects of psilocybin on empathy, creative thinking, and subjective well-being","volume":"51","author":"Mason","year":"2019","journal-title":"J. Psychoact. Drugs"},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110413_bib123","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1034\/j.1600-0447.2000.102004256.x","article-title":"The collaborative longitudinal personality disorders study: baseline Axis I\/II and II\/II diagnostic co-occurrence","volume":"102","author":"McGlashan","year":"2000","journal-title":"Acta Psychiatr. Scand."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110413_bib124","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1001\/archpsyc.1971.01750070037005","article-title":"LSD revisited. A ten-year follow-up of medical LSD use","volume":"24","author":"McGlothlin","year":"1971","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.neuropharm.2025.110413_bib125","unstructured":"Mitra, P., Torrico, T.J., Fluyau, D. [updated 2024 March 1]. In StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from https:\/\/www.ncib.nlm.nih.gov\/books\/NBK556001\/."},{"key":"10.1016\/j.neuropharm.2025.110413_bib126","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2023.1098452","article-title":"Dimensional models of personality disorders: challenges and opportunities","volume":"14","author":"Monaghan","year":"2023","journal-title":"Front. Psychiatr."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110413_bib127","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1037\/per0000551","article-title":"Criterion A: level of personality functioning in the alternative DSM\u20135 model for personality disorders","volume":"13","author":"Morey","year":"2022","journal-title":"Personality Disorders: Theory, Res. Treat."},{"key":"10.1016\/j.neuropharm.2025.110413_bib128","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2020.573953","article-title":"Treatment of a complex personality disorder using repeated doses of LSD\u2014a case report on significant improvements in the absence of acute drug effects","volume":"11","author":"M\u00fcller","year":"2020","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.neuropharm.2025.110413_bib129","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.655548","article-title":"ICD-11 personality disorders: utility and implications of the new model","volume":"12","author":"Mulder","year":"2021","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.neuropharm.2025.110413_bib130","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.788155","article-title":"Therapeutic alliance and rapport modulate responses to psilocybin-assisted therapy for depression","volume":"12","author":"Murphy","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110413_bib132","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2023.1199642","article-title":"Naturalistic psilocybin use is associated with persisting improvements in mental health and wellbeing: results from a prospective, longitudinal survey","volume":"14","author":"Nayak","year":"2023","journal-title":"Front. Psychiatr."},{"issue":"10","key":"10.1016\/j.neuropharm.2025.110413_bib133","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1007\/s00213-020-05601-0","article-title":"Modulatory effects of ayahuasca on personality structure in a traditional framework","volume":"237","author":"Netzband","year":"2020","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110413_bib134","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1124\/pr.115.011478","article-title":"Psychedelics","volume":"68","author":"Nichols","year":"2016","journal-title":"Pharmacol. Rev."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110413_bib135","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/cpt.557","article-title":"Psychedelics as medicines: an emerging new paradigm","volume":"101","author":"Nichols","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2025.110413_bib136","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3389\/fphar.2018.00132","article-title":"The psychedelic debriefing in alcohol dependence treatment: illustrating key change phenomena through qualitative content analysis of clinical sessions","volume":"9","author":"Nielson","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110413_bib137","series-title":"San Jose, CA, Multidisciplinary Association for Psychedelic Studies","article-title":"Statement: public announcement of ethical violation by former MAPS-sponsored investigators","author":"Noble","year":"2019"},{"issue":"7","key":"10.1016\/j.neuropharm.2025.110413_bib138","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1177\/0269881118780612","article-title":"Psychedelic therapy for smoking cessation: qualitative analysis of participant accounts","volume":"32","author":"Noorani","year":"2018","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2025.110413_bib139","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3389\/fnhum.2016.00269","article-title":"Ego-dissolution and psychedelics: validation of the ego-dissolution inventory (EDI)","volume":"10","author":"Nour","year":"2016","journal-title":"Front. Hum. Neurosci."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110413_bib140","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1176\/appi.ajp.20230887","article-title":"Multi-dimensional personality changes following psilocybin-assisted therapy in patients with alcohol use disorder: results from a double-blind, placebo-controlled clinical trial","volume":"182","author":"Pagni","year":"2025","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2025.110413_bib141","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/02791072.2025.2465800","article-title":"Long-term mental health and wellbeing outcomes associated with naturalistic ayahuasca consumption","author":"Pagni","year":"2025","journal-title":"J. Psychoact. Drugs"},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110413_bib142","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1017\/S0033291718001356","article-title":"Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial","volume":"49","author":"Palhano-Fontes","year":"2019","journal-title":"Psychol. Med."},{"key":"10.1016\/j.neuropharm.2025.110413_bib143","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.1020505","article-title":"Lower-dose psycholytic therapy \u2013 a neglected approach","volume":"13","author":"Passie","year":"2022","journal-title":"Front. Psychiatr."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110413_bib144","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/02698811211066709","article-title":"Validation of the Psychological Insight Scale: a new scale to assess psychological insight following a psychedelic experience","volume":"36","author":"Peill","year":"2022","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2025.110413_bib145","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.884703","article-title":"Changes in mental health, wellbeing and personality following ayahuasca consumption: results of a naturalistic longitudinal study","volume":"13","author":"Perkins","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110413_bib146","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.psychres.2016.08.015","article-title":"The relationship of depersonalization and absorption to hallucinations in psychotic and non-clinical participants","volume":"244","author":"Perona-Garcel\u00e1n","year":"2016","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.neuropharm.2025.110413_bib147","doi-asserted-by":"crossref","DOI":"10.1038\/s44220-024-00331-0","article-title":"Psilocybin-assisted psychotherapy improves psychiatric symptoms across multiple dimensions in patients with cancer","author":"Petridis","year":"2024","journal-title":"Nature Mental Health"},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110413_bib148","first-page":"211","article-title":"A pilot study of the effect of group-administered psilocybin on psychological flexibility and outcomes","volume":"8","author":"Pilecki","year":"2024","journal-title":"J. Psychedelic Stud."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110413_bib149","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1176\/appi.focus.20220058","article-title":"Obsessive-compulsive personality disorder: a review of symptomatology, impact on functioning, and treatment","volume":"20","author":"Pinto","year":"2022","journal-title":"Focus: J. Lifelong Learn. Psychiatry"},{"issue":"9","key":"10.1016\/j.neuropharm.2025.110413_bib150","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1093\/ijnp\/pyx047","article-title":"Effect of psilocybin on empathy and moral decision-making","volume":"20","author":"Pokorny","year":"2017","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"12","key":"10.1016\/j.neuropharm.2025.110413_bib151","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults","volume":"168","author":"Posner","year":"2011","journal-title":"Am. J. Psychiatr."},{"issue":"S1","key":"10.1016\/j.neuropharm.2025.110413_bib152","first-page":"1","article-title":"The effect of 5-HT2A\/1a agonist treatment on social cognition, empathy, and social decision-making","volume":"30","author":"Preller","year":"2015","journal-title":"Eur. Psychiatry"},{"issue":"9","key":"10.1016\/j.neuropharm.2025.110413_bib153","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jama.2023.14530","article-title":"Single-dose psilocybin treatment for major depressive disorder","volume":"330","author":"Raison","year":"2023","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110413_bib154","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1176\/appi.focus.11.2.225","article-title":"Evidence-based pharmacotherapy for personality disorders","volume":"11","author":"Ripoll","year":"2013","journal-title":"Focus"},{"key":"10.1016\/j.neuropharm.2025.110413_bib155","doi-asserted-by":"crossref","first-page":"974","DOI":"10.3389\/fphar.2017.00974","article-title":"Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression","volume":"8","author":"Roseman","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110413_bib156","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.concog.2017.01.015","article-title":"Immersion in altered experience: an investigation of the relationship between absorption and psychopathology","volume":"49","author":"Rosen","year":"2017","journal-title":"Conscious. Cognit."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110413_bib157","first-page":"190","article-title":"Psilocybin-assisted psychotherapy for treatment-resistant depression: a randomized clinical trial evaluating repeated doses of psilocybin","volume":"5","author":"Rosenblat","year":"2024","journal-title":"M\u00e9dica Sur"},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110413_bib158","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/WNF.0b013e318261e193","article-title":"Co-occurring psychotic and addictive disorders: neurobiology and diagnosis","volume":"35","author":"Ross","year":"2012","journal-title":"Clin. Neuropharmacol."},{"issue":"12","key":"10.1016\/j.neuropharm.2025.110413_bib159","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial","volume":"30","author":"Ross","year":"2016","journal-title":"J. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110413_bib160","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1021\/acsptsci.1c00020","article-title":"Acute and sustained reductions in loss of meaning and suicidal ideation following psilocybin-assisted psychotherapy for psychiatric and existential distress in life-threatening cancer","volume":"4","author":"Ross","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110413_bib161","first-page":"59","article-title":"The effectiveness of psychedelic (LSD) therapy: a preliminary report","volume":"2","author":"Savage","year":"1967","journal-title":"British J. Social Psychiat."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110413_bib162","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00213-017-4733-3","article-title":"Long-lasting subjective effects of LSD in normal subjects","volume":"235","author":"Schmid","year":"2018","journal-title":"Psychopharmacology"},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110413_bib163","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/00005053-196706000-00004","article-title":"Therapeutic effects of LSD: a follow-up study","volume":"144","author":"Shagass","year":"1967","journal-title":"J. Nerv. Ment. Dis."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110413_bib164","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/02791072.2022.2054746","article-title":"Magic mushroom use: a qualitative interview study of post-trip impacts and strategies for optimizing experiences","volume":"55","author":"Shaw","year":"2023","journal-title":"J. Psychoact. Drugs"},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110413_bib165","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1521\/pedi.2024.38.4.368","article-title":"Comparing the DSM-5 dimensional trait and triarchic model conceptions of psychopathy: an external validity analysis","volume":"38","author":"Sica","year":"2024","journal-title":"J. Pers. Disord."},{"key":"10.1016\/j.neuropharm.2025.110413_bib166","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.copsyc.2017.09.006","article-title":"Impact of personality pathology on psychosocial functioning","volume":"21","author":"Skodol","year":"2018","journal-title":"Curr. Opinion Psychol."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110413_bib167","doi-asserted-by":"crossref","first-page":"8833","DOI":"10.1038\/s41598-024-58318-x","article-title":"Psychological flexibility as a mechanism of change in psilocybin-assisted therapy for major depression: results from an exploratory placebo-controlled trial","volume":"14","author":"Sloshower","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2025.110413_bib168","article-title":"Ethics and ego dissolution: the case of psilocybin","author":"Smith","year":"2022","journal-title":"J. Med. Ethics"},{"issue":"140","key":"10.1016\/j.neuropharm.2025.110413_bib169","article-title":"Mysticism and philosophy","volume":"37","author":"Stace","year":"1960","journal-title":"Philosophy"},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110413_bib170","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1021\/acsptsci.0c00169","article-title":"Psilocybin-assisted group therapy and attachment: observed reduction in attachment anxiety and influences of attachment insecurity on the psilocybin experience","volume":"4","author":"Stauffer","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110413_bib171","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030800","article-title":"Prediction of psilocybin response in healthy volunteers","volume":"7","author":"Studerus","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110413_bib172","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1177\/02698811211008554","article-title":"Psychedelics and health behaviour change","volume":"36","author":"Teixeira","year":"2022","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2025.110413_bib173","first-page":"459","article-title":"Group therapy with LSD-25: a preliminary report","volume":"22","author":"Tenenbaum","year":"1961","journal-title":"Dis. Nerv. Syst."},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110413_bib174","doi-asserted-by":"crossref","DOI":"10.1192\/bjo.2023.592","article-title":"Polypharmacy in the treatment of people diagnosed with borderline personality disorder: repeated cross-sectional study using New Zealand's national databases","volume":"9","author":"Tennant","year":"2023","journal-title":"BJPsych Open"},{"issue":"7","key":"10.1016\/j.neuropharm.2025.110413_bib175","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1177\/0269881118771782","article-title":"Psychedelic use and intimate partner violence: the role of emotion regulation","volume":"32","author":"Thiessen","year":"2018","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2025.110413_bib176","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.avb.2016.02.004","article-title":"Recreational drug use and human aggressive behavior: a comprehensive review since 2003","volume":"27","author":"Tomlinson","year":"2016","journal-title":"Aggress. Violent Behav."},{"issue":"7","key":"10.1016\/j.neuropharm.2025.110413_bib208","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1007\/s00213-021-05817-8","article-title":"A placebo-controlled study of the effects of ayahuasca, set and setting on mental health pf participants in ayahuasca group retreats","volume":"238","author":"Uthaug","year":"2021","journal-title":"Psychopharmacology"},{"issue":"10","key":"10.1016\/j.neuropharm.2025.110413_bib177","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1007\/s00213-018-4988-3","article-title":"Sub-acute and long-term effects of ayahuasca on affect and cognitive thinking style and their association with ego dissolution","volume":"235","author":"Uthaug","year":"2018","journal-title":"Psychopharmacology"},{"issue":"17","key":"10.1016\/j.neuropharm.2025.110413_bib178","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1097\/00001756-199812010-00024","article-title":"Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action","volume":"9","author":"Vollenweider","year":"1998","journal-title":"Neuroreport"},{"key":"10.1016\/j.neuropharm.2025.110413_bib179","article-title":"Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial","volume":"56","author":"von Rotz","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110413_bib180","doi-asserted-by":"crossref","first-page":"555","DOI":"10.18553\/jmcp.2019.25.5.555","article-title":"Real-world direct health care costs associated with psychotropic polypharmacy among adults with common cancer types in the United States","volume":"25","author":"Vyas","year":"2019","journal-title":"J. Manag. Care Specialty Pham."},{"issue":"7","key":"10.1016\/j.neuropharm.2025.110413_bib181","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1177\/0269881116642538","article-title":"Hallucinogen use and intimate partner violence: prospective evidence consistent with protective effects among men with histories of problematic substance use","volume":"30","author":"Walsh","year":"2016","journal-title":"J. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110413_bib182","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1177\/0022167817709585","article-title":"Patients' accounts of increased \u201cconnectedness\u201d and \u201cacceptance\u201d after psilocybin for treatment-resistant depression","volume":"57","author":"Watts","year":"2017","journal-title":"J. Humanist. Psychol."},{"issue":"11","key":"10.1016\/j.neuropharm.2025.110413_bib183","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1007\/s00213-022-06187-5","article-title":"The Watts Connectedness Scale: a new scale for measuring a sense of connectedness to self, others, and world","volume":"239","author":"Watts","year":"2022","journal-title":"Psychopharmacology"},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110413_bib184","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11920-016-0665-6","article-title":"Avoidant personality disorder: a current review","volume":"18","author":"Weinbrecht","year":"2016","journal-title":"Curr. Psychiatry Rep."},{"key":"10.1016\/j.neuropharm.2025.110413_bib185","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyg.2021.749788","article-title":"Examining psychedelic-induced changes in social functioning and connectedness in a naturalistic online sample using the Five-Factor Model of personality","volume":"12","author":"Weiss","year":"2021","journal-title":"Front. Psychol."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110413_bib186","doi-asserted-by":"crossref","first-page":"4580","DOI":"10.1038\/s41598-021-84746-0","article-title":"Examining changes in personality following shamanic ceremonial use of ayahuasca","volume":"11","author":"Weiss","year":"2021","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110413_bib187","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1556\/2054.2023.00291","article-title":"Perceptions of psychedelic personality change, determinants of use, setting and drug moderation: toward a holistic model","volume":"7","author":"Weiss","year":"2023","journal-title":"J. Psychedelic Stud."},{"key":"10.1016\/j.neuropharm.2025.110413_bib188","article-title":"Ayahuasca in the treatment of posttraumatic stress disorder: mixed-methods case series evaluation in military combat veterans","author":"Weiss","year":"2023","journal-title":"Psychological Trauma: Theory, Research, Practice, and Policy"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110413_bib189","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1017\/S0033291723001514","article-title":"Personality change in a trial of psilocybin therapy vs. escitalopram treatment for depression","volume":"54","author":"Weiss","year":"2024","journal-title":"Psychol. Med."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110413_bib190","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1007\/s11469-024-01253-9","article-title":"Unique psychological mechanisms underlying psilocybin therapy versus escitalopram treatment in the treatment of major depressive disorder","volume":"22","author":"Weiss","year":"2024","journal-title":"Int. J. Ment. Health Addiction"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110413_bib191","doi-asserted-by":"crossref","first-page":"5","DOI":"10.5694\/j.1326-5377.1964.tb133752.x","article-title":"Lysergic acid diethylamide in psychotherapy. Part I: clinical aspects","volume":"1","author":"Whitaker","year":"1964","journal-title":"Med. J. Aust."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110413_bib192","doi-asserted-by":"crossref","first-page":"36","DOI":"10.5694\/j.1326-5377.1964.tb133783.x","article-title":"Lysergic acid diethylamide in psychotherapy","volume":"1","author":"Whitaker","year":"1964","journal-title":"Med. J. Aust."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110413_bib194","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1037\/0003-066X.62.2.71","article-title":"Plate tectonics in the classification of personality disorder: shifting to a dimensional model","volume":"62","author":"Widiger","year":"2007","journal-title":"Am. Psychol."},{"key":"10.1016\/j.neuropharm.2025.110413_bib195","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jrp.2019.04.008","article-title":"HiTOP thought disorder, DSM-5 psychoticism, and five factor model openness","volume":"80","author":"Widiger","year":"2019","journal-title":"J. Res. Pers."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110413_bib196","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1037\/0022-3514.69.3.569","article-title":"The role of absorption in experiential involvement","volume":"69","author":"Wild","year":"1995","journal-title":"J. Pers. Soc. Psychol."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110413_bib197","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1556\/2054.2022.00192","article-title":"Psychedelic-supportive psychotherapy: a psychotherapeutic model for, before, and beyond the medicine experience","volume":"6","author":"Wolfson","year":"2023","journal-title":"J. Psychedelic Stud."},{"key":"10.1016\/j.neuropharm.2025.110413_bib199","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.3389\/fphar.2019.01325","article-title":"The impact of ayahuasca on suicidality: results from a randomized controlled trial","volume":"10","author":"Zeifman","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110413_bib200","doi-asserted-by":"crossref","first-page":"782","DOI":"10.3389\/fpsyt.2020.00782","article-title":"Post-psychedelic reductions in experiential avoidance are associated with decreases in depression severity and suicidal ideation","volume":"11","author":"Zeifman","year":"2020","journal-title":"Front. Psychiatr."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110413_bib201","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00213-020-05692-9","article-title":"Rapid and sustained decreases in suicidality following a single dose of ayahuasca among individuals with recurrent major depressive disorder: results from an open-label trial","volume":"238","author":"Zeifman","year":"2021","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110413_bib202","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.21r14057","article-title":"Decreases in suicidality following psychedelic therapy: a meta-analysis of individual patient data across clinical trials","volume":"83","author":"Zeifman","year":"2022","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.neuropharm.2025.110413_bib203","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jad.2023.04.105","article-title":"How does psilocybin therapy work? An exploration of experiential avoidance as a putative mechanism of change","volume":"334","author":"Zeifman","year":"2023","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.neuropharm.2025.110413_bib204","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-40856-5","article-title":"Co-use of MDMA with psilocybin\/LSD may buffer against challenging experiences and enhance positive experiences","volume":"13","author":"Zeifman","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2025.110413_bib205","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.euroneuro.2023.09.007","article-title":"Methodological concerns in psychedelic research: the issues of nonequivalent psychological support and generalizability","volume":"78","author":"Zeifman","year":"2024","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110413_bib206","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1038\/s41598-023-28111-3","article-title":"From relaxed beliefs under psychedelics (REBUS) to revised beliefs after psychedelics (REBAS)","volume":"15","author":"Zeifman","year":"2025","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110413_bib207","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1037\/abn0000059","article-title":"The latent structure of personality functioning: investigating Criterion A from the alternative model for personality disorders in DSM-5","volume":"124","author":"Zimmermann","year":"2015","journal-title":"J. Abnorm. Psychol."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825001194?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825001194?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T23:58:24Z","timestamp":1762214304000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390825001194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":204,"alternative-id":["S0028390825001194"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110413","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring serotonergic psychedelics as a treatment for personality disorders","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110413","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110413"}}